Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate

University of North Carolina, Chapel Hill50 enrolled

Overview

The purpose of this study is to assess continuation rates and patient satisfaction with self administration subcutaneous depot medroxyprogesterone acetate.

This observational study will include new or current Depo Provera users who express interest in attempting subcutaneous self administration of depot medroxyprogesterone acetate. Candidates will be taught self administration by a clinic assistant at Planned Parenthood of Southwest and Central Florida. Patients who are able to correctly self administer the medication and wish to attempt to continue home self administration, will be provided the supplies and educational materials to do so. Continuation rates and satisfaction with this method will be assessed using preaddressed surveys that patients will return with the above information.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Fertility

Interventions

Self administrationPROCEDURE

Subjects will self administer injections of 104 mg of the subcutaneous formulation of depot medroxyprogesterone acetate (depo-subQ provera 104).

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Women 18 years or older * Can understand written and spoken English * Current or past user of DMPA or desires initiation of DMPA for contraception * Provider has approved DMPA use in this woman * Willing to consider/attempt DMPA self-injection. * Willing to receive phone calls/letter for follow up * Willing to return letters for follow up Exclusion Criteria: Has contraindications to DMPA use: * Vaginal bleeding of unknown etiology * Medication use for Cushing's syndrome * Currently pregnant * Blood pressure \>160/100 * Intolerance to the idea of irregular or absent menses

Locations (2)

Planned Parenthood of Southwest and Central Florida

Fort Myers, Florida, United States

Planned Parenthood of Southwest and Central Florida

Tampa, Florida, United States

Outcomes

Primary Outcomes

Patient satisfaction with/feasibility of self injection of subcutaneous depot medroxyprogesterone acetate

Time frame: At onset of trial and every 12 weeks for 1 year

Secondary Outcomes

Continuation rates of depot medroxyprogesterone acetate among self-injectors

Time frame: Every 12 weeks for 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.